

SASKATOON HEALTH REGION
Saskatoon, Saskatchewan

BUH SOH SPH OTHER _____

Any PRINTED version of this document is only accurate up to the date this document was developed. SHR can not guarantee the currency or accuracy of any printed policy. SHR accepts no responsibility for use of this material by any person or organization not associated with SHR. No part of this document may be reproduced in any form for publication without permission of SHR.

SAMPLE ONLY
Master Copy in Printing Services

PHYSICIAN'S ORDERS

ALLERGIES: _____

DATE	TIME	ORDERS AND SIGNATURE	PROCESSED				
			TIME	M A R	I C P	R E Q	R N

Acute Coronary Syndrome (ACS)
EPTIFIBATIDE for Non-ST-Elevation

Patient Weight = _____ kg

1. Platelets 6 hours after eptifibatide loading dose at _____.
2. CBC/platelets daily; and with major bleeding.
3. CBC/platelets 24 hours after discontinuing eptifibatide infusion or prior to discharge; whichever occurs first.
4. If platelets decreased to _____, contact physician immediately.

5. **Eptifibatide Therapy:** **NO** contraindications to Eptifibatide. **See reverse**
Patient Serum Creatinine = _____ mcmol/L

Maintenance infusion is dependent on renal function. Select column matching patient's serum creatinine. Maintenance infusion can be continued for up to 72 hours. Maintenance infusion should be continued for 18 to 24 hours following PCI. The total infusion time should not exceed 96 hours.

Patient Weight (kg)	Bolus Dose IV push over 1 – 2 min. Dosage = 180 mcg/kg 2mg/mL 10mL vial	Maintenance Infusion Rate Hang 100 mL (0.75 mg/mL) vial using a vented set	
		<input type="checkbox"/> Serum Creatinine less than 175 mcmol/L Dosage: 2 mcg/kg/min	<input type="checkbox"/> Serum Creatinine Greater than 175 mcmol/L Dosage: 1 mcg/kg/min (Use with caution if serum creatinine greater than 360 mcmol/L)
<input type="checkbox"/> 37 – 41	3.4 mL	6 mL/hour	3 mL/hour
<input type="checkbox"/> 42 – 46	4 mL	7 mL/hour	3.5 mL/hour
<input type="checkbox"/> 47 – 53	4.5 mL	8 mL/hour	4 mL/hour
<input type="checkbox"/> 54 – 59	5 mL	9 mL/hour	4.5 mL/hour
<input type="checkbox"/> 60 – 65	5.6 mL	10 mL/hour	5 mL/hour
<input type="checkbox"/> 66 – 71	6.2 mL	11 mL/hour	5.5 mL/hour
<input type="checkbox"/> 72 – 78	6.8 mL	12 mL/hour	6 mL/hour
<input type="checkbox"/> 79 – 84	7.3 mL	13 mL/hour	6.5 mL/hour
<input type="checkbox"/> 85 – 90	7.9 mL	14 mL/hour	7 mL/hour
<input type="checkbox"/> 91 – 96	8.5 mL	15 mL/hour	7.5 mL/hour
<input type="checkbox"/> 97 – 103	9 mL	16 mL/hour	8 mL/hour
<input type="checkbox"/> 104 – 109	9.5 mL	17 mL/hour	8.5 mL/hour
<input type="checkbox"/> 110 – 115	10.2 mL	18 mL/hour	9 mL/hour
<input type="checkbox"/> 116 – 121	10.7 mL	19 mL/hour	9.5 mL/hour
<input type="checkbox"/> 122 or greater	11.3 mL	20 mL/hour	10 mL/hour

Physician's Signature: _____
Print Physician Name: _____

Contraindications to Eptifibatide

- active internal bleeding or history of bleeding diathesis
- severe hypertension (Sys-BP greater than 180mmHg or Diastolic BP greater than 110mmHg)
- major surgery or trauma within 6 weeks
- history of intracranial hemorrhage, neoplasm, arteriovenous malformation or aneurysm
- acute pericarditis
- history of cerebrovascular accident (stroke) within 30 days, or any history of hemorrhagic stroke
- thrombocytopenia (platelets less than 100,000)
- increased risk of bleeding (prothrombin time greater than 1.2 times control)
- clinically significant liver disease
- history, symptoms or findings suggestive of aortic dissection

PRECAUTIONS: Serum creatinine greater than 360 mcmol/L, current use of anticoagulants, and clinically significant liver disease.